Published in final edited form as:

Nat Rev Mol Cell Biol. 2011 May ; 12(5): 283–294. doi:10.1038/nrm3098.

Unravelling the means to an end: RNA polymerase II transcription termination

Jason N. Kuehner, Erika L. Pearson, Claire Moore

Department of Molecular Biology and Microbiology, Tufts University School of Medicine, 150 Harrison Avenue, Boston, Massachusetts 02111, USA.

Abstract

The pervasiveness of RNA synthesis in eukaryotes is largely the result of RNA polymerase II (Pol II)-mediated transcription, and termination of its activity is necessary to partition the genome and maintain the proper expression of neighbouring genes. Despite its ever-increasing biological significance, transcription termination remains one of the least understood processes in gene expression. However, recent mechanistic studies have revealed a striking convergence among several overlapping models of termination, including the poly(A)- and Sen1-dependent pathways, as well as new insights into the specificity of Pol II termination among its diverse gene targets. Broader knowledge of the role of Pol II carboxy-terminal domain phosphorylation in promoting alternative mechanisms of termination has also been gained.

Table of contents

Transcription termination is one of the least-understood processes in gene expression. However, recent studies have revealed common themes and principles between models of RNA polymerase II termination, including the poly(A)-dependent and Sen1-dependent pathways, and provided insight into the role of Pol II carboxy-terminal domain phosphorylation in this process.

Keywords

Gene expression

Regulation of gene expression, which is essential for normal cellular development and homeostasis, often occurs at the level of transcription. In eukaryotes, nuclear RNA polymerase II (Pol II) is responsible for synthesizing all protein-coding RNAs and most non-

Correspondence to C.M. claire.moore@tufts.edu.

Competing interests statement

The authors declare no competing financial interests.

DATABASES

Protein Data Bank: <http://www.rcsb.org/pdb1I3Q1Y1W3LU0>

PyMOL: <http://www.pymol.org/>

FURTHER INFORMATION

<http://sackler.tufts.edu/Academics/Degree-Programs/PhD-Programs/Faculty-Research-Pages/Claire-Moore.aspx>

SUPPLEMENTARY INFORMATION

See online article: S1 (table)

coding RNAs, including small nuclear RNAs (snRNAs), small nucleolar RNAs (snoRNAs), microRNAs (miRNAs), cryptic unstable transcripts (CUTs) and stable untranslated transcripts (SUTs). Pol II is subject to regulatory control at all stages of the transcription cycle, including initiation, elongation and termination (FIG. 1a). During the first stage of initiation, Pol II is recruited to a gene promoter, the DNA is melted to expose the template strand and the first few nucleotides of RNA are synthesized. Pol II escapes from the promoter when RNA reaches a length of ~8–9 nucleotides, which constitutes the full length of the DNA-RNA hybrid that is observed during the elongation stage. Termination occurs when Pol II ceases RNA synthesis and both Pol II and the nascent RNA are released from the DNA template. Perhaps owing to its foremost position in the cycle, initiation is the best-understood process of transcription in terms of both its mechanism and regulation¹. More recently, the transition from initiation to elongation has been better defined, and the regulation of this transition by promoterproximal pausing has emerged as an important and widespread phenomenon^{2,3}. Much less is known about the mechanism and regulation of Pol II transcription termination.

Transcription termination serves many vital functions in the cell. For example, it prevents Pol II from interfering with downstream DNA elements, such as promoters, and promotes polymerase recycling^{4–6}. Contrary to being limited to a constitutive process at the end of a gene, transcription termination is dynamic and can occur upstream, downstream and within open reading frames (ORFs). The idea that termination could be modulated initially came from studies in bacteria, which revealed that premature termination (that is, attenuation) is a sensitive means to regulate clusters of amino acid biosynthesis genes^{7,8}. When the amino acid product encoded by these genes is present in excess, an RNA terminator forms within the 5′ untranslated region (UTR) of the mRNA and leads to the release of RNA polymerase before transcription of the protein-coding region. This particular example takes advantage of intrinsic RNA folding and coupled transcription and translation in bacteria, but other variations of attenuation are mediated through RNA-binding proteins and function independently of ribosome activity⁸.

The discovery, and ongoing investigation, of attenuation-based regulatory strategies in viruses (for example, HIV) and eukaryotic organisms has substantiated transcription termination as a widespread and versatile target for controlling gene expression^{5,9,10}. The importance of termination in genomic partitioning has become all the more compelling with the recent revelation that transcription is not limited to discrete functional units such as ORFs, but rather that genomes are almost entirely transcribed¹¹. The high volume of DNA traffic resulting from genome-wide transcription requires that RNA polymerases terminate efficiently to avoid interfering with neighbouring transcriptional units¹². Recent studies have also shown that defective termination at the 3′ end of a gene has a greater impact on mRNA synthesis than previously expected. It leads to decreased splicing and increased degradation of the RNA¹³, as well as reduced initiation at the gene's promoter, perhaps as a means to shut down transcription when termination fails¹⁴. As Pol II termination is coupled with RNA 3′-end processing, the timing of Pol II release can also dictate the length of the final RNA product and thus affect the stability, localization and ultimate functionality of nascent transcripts.

A comprehensive chronicle of eukaryotic transcription termination by all of the major nuclear RNA polymerases was expertly discussed a short time ago⁶ and is not the focus of this Review. Instead, we concentrate on the most recent findings pertaining to Pol II transcription termination, and particularly on the selection, usage and functional outcome of alternative termination pathways in the model eukaryote *Saccharomyces cerevisiae*. The corresponding human termination pathways are discussed where appropriate. We also compare models of Pol II termination with better-characterized examples from bacterial transcription termination, and expound on the possibility of a general and conserved allosteric mechanism for all cellular RNA polymerases.

Pol II termination pathways

Although the release of RNA polymerase and its product are clearly important, these events must be balanced with the needs of a cell to transcribe genes quickly and completely. The remarkable speed of the Pol II elongation complex (~1–4 kb per min (REF. 15)), and its processivity, depends on an intricate network of interactions between polymerase proteins and nucleic acids (DNA and RNA) and base-pairing interactions between single-stranded RNA and DNA. The RNA-DNA hybrid of 8 nucleotides in length that is maintained during the elongation stage has been proposed to be the primary stability determinant of Pol II^{16,17}, and as such, disruption of this heteroduplex may be the pivotal event that results in termination (FIG. 1). Pol II termination can be elicited through different pathways, depending on the RNA 3'-end processing signals and termination factors that are present at the end of a gene^{6,18,19}. Two of the best-studied pathways, the poly(A)-dependent pathway and the Sen1-dependent pathway, are presented below to illustrate common themes and principles involved in termination. An extensive collection of termination factors has been revealed, and mutational analysis has helped tease apart some of the dual roles that these proteins serve in the relevant RNA processing and termination decisions (table 1; also see Supplementary information S1 (table)).

Poly(A)-dependent termination.

Pol II termination downstream of most protein-coding genes is functionally coupled with an RNA maturation event in which the 3' end of the nascent transcript undergoes cleavage and polyadenylation^{20,21} (FIG. 2a). This 3'-end processing reaction can be broken down into two steps: first, transcription of a poly(A) site is followed by pausing of Pol II transcription and endoribonucleolytic cleavage of the nascent transcript; and second, the upstream cleavage product is polyadenylated, whereas the downstream cleavage product is degraded. The 3'-end processing reaction is initiated when cis-acting elements in the poly(A) site of the nascent transcript are recognized by RNA-binding factors that associate with Pol II, and the efficiency of termination correlates well with the strength of the poly(A) site^{22–24}. The 3'-end processing machinery that carries out this seemingly simple reaction is highly complex, comprising more than 20 polypeptides in yeast and over 14 proteins in mammals^{25,26}. An exhaustive analysis of the factors associated with the core mammalian 3'-end processing machinery recovered over 80 proteins, many of which mediate crosstalk with other co-transcriptional processes²⁷.

A key scaffold for the recruitment of Pol II termination factors is the extended unstructured carboxy-terminal domain (CTD) of its Rpb1 subunit. The Pol II CTD consists of tandem heptad repeats (26 in yeast, 52 in human), which are made up primarily of the amino acid consensus sequence Tyr₁-Ser₂-Pro₃-Thr₄-Ser₅-Pro₆-Ser₇. The CTD is targeted by a wide range of post-translational modifications, of which the best-studied is phosphorylation^{28,29}. As Pol II progresses through different stages of transcription, changes in the pattern of CTD phosphorylation alter the affinity of CTD-binding proteins, suggesting that a CTD code may regulate Pol II function³⁰ (FIG. 1b). Binding of 3'-end processing factors to the Pol II CTD and to RNA could transmit enough force to shear the active site RNA-DNA hybrid. However, this association may also make Pol II more susceptible to pausing, which has been observed several-hundred base pairs beyond the poly(A) site on many human genes^{31,32}. Maximal recruitment of cleavage and polyadenylation factors coincides with paused Pol II³². Elegant *in vitro* studies from the Martinson laboratory^{33–35} using cell extracts show that transcription through a poly(A) signal reduces the rate of Pol II elongation and causes pausing downstream of the poly(A) site. These findings support a model in which the human cleavage and polyadenylation specificity factor (CPSF; homologous to cleavage and polyadenylation factor (CPF) in yeast) is recruited to the elongation complex by interaction with the Pol II body, whereas the cleavage stimulatory factor (CstF; homologous to cleavage factor IA (CFIA) in yeast) interacts with the CTD (FIG. 2c, step 1). Then, when the AAUAAA sequence that CPSF recognizes is transcribed, CPSF binding to this site induces pausing. When CstF binds to the downstream GU-rich processing signal, CPSF binds to CstF, releases its hold on the Pol II body and accompanies CstF to the CTD, leading to CPSF-mediated cleavage and release of the paused Pol II (FIG. 2c, steps 2 and 3).

Thus, pausing appears to be an important intermediate step leading to termination in many mammalian genes. However, pausing of Pol II per se does not lead to termination. For example, Pol II pauses at other positions in a gene, such as just proximal to the promoters of inducible metazoan genes³ or in terminal exons in yeast genes, as a way to allow sufficient time for splicing^{36,37}. Efficient release of Pol II paused downstream of a poly(A) site requires not only 3'-end processing factors, such as CPF and CFIA, but also the 5'–3' exoribonuclease RNA-trafficking protein 1 (Rati; XRN2 in mammals) in complex with its activating cofactor Rati-interacting 1 (Rai1) and its CTD-interacting partner regulator of Ty1 transposition 103 (Rtt103)^{38,39} (FIGS 2a,c). In what has been called the 'torpedo' model, Rat1 is recruited to the 3' end of the gene via interactions of the CTD with 3'-end processing factors and with Rtt103 (REFS 40,41). Creation of an unprotected 5' end by the 3'-end processing endoribonuclease, or by other cleavage events downstream of the poly(A) site^{42–45}, allows Rat1 (or XRN2) to rapidly 'chew' its way along the RNA tether to the RNA exit channel on Pol II. Collision of Rat1 (or XRN2) with Pol II would then promote termination^{38,39,46} (FIGS 2a,c). In this scenario, the function of the 3'-end processing complex is to help recruit Rat1 to the Pol II CTD, to introduce an entry site for Rat1 and to induce a pause or slowing of Pol II that allows Rat1 to quickly catch up with the polymerase. The pause may also give the processing complex time to assemble and cleave the transcript. Combined with the Rat1 torpedo, the allosteric changes that slow Pol II and perhaps loosen its grip on the DNA template lead to destabilization of Pol II and its release.

Sen1-dependent termination.

An alternative Pol II termination pathway for most non-coding RNAs was first discovered in the yeast *S. cerevisiae* (FIG. 2b). Unlike mRNAs, the 3'-ends of yeast snRNAs and snoRNAs are generated by endoribonucleolytic cleavage and/or exoribonucleolytic trimming by the nuclear exosome-TRAMP complex and do not possess a poly(A) tail in their mature form⁴⁷. A distinct set of core factors is required for recognition and transduction of the transcription termination signal, including the RNA-binding proteins Nrd1 and nuclear polyadenylated RNA-binding 3 (Nab3) and the putative RNA and DNA helicase Sen1 (REFS 48–51), which is also needed for 3'-end processing of non-coding RNAs^{52,53} and the resolution of R-loops formed during transcription⁵⁴ (FIG. 2b). In addition to targeting snRNAs and snoRNAs, the Sen1-dependent pathway is required for termination of CUTs^{55,56}. Several mRNA 3'-end processing factors contribute to the transcription termination of non-coding RNAs (TABLE 1). As with the poly(A)-dependent mechanism, the interaction of these factors with the Pol II CTD and with their RNA-binding sites could provoke conformational changes. However, instead of a collision with Rat1 dislodging Pol II, in this pathway Sen1 is proposed to terminate Pol II by unwinding the RNA-DNA hybrid in the active site⁴⁸, analogously to the proposed action of bacterial Rho helicase⁵⁷. Sen1, and its human homologue senataxin, also contributes to poly(A)-dependent termination^{58–60}, and short mRNA-encoding genes are particularly susceptible to loss of Sen1 function⁵¹. The role of Sen1 in poly(A)-dependent termination is as yet unknown, but it has been speculated to make RNA more accessible to Rat1 by removing proteins or RNA secondary structure⁵⁸.

It remains to be seen if a distinct type of termination pathway targets non-coding RNAs in higher eukaryotes. Unlike their homologues in yeast, most of the mammalian snoRNAs are encoded within introns and termination is not needed in this arrangement⁶¹. However, most metazoan snRNAs are transcribed from independent genes, and a promoter-specific pre-initiation complex helps to recruit the integrator complex that mediates 3'-end cleavage of the primary transcripts^{62,63}. Interestingly, the integrator complex contains homologues to the mRNA 3'-end processing factors CPSF73 and CPSF100 (REFS 64,65), suggesting that metazoan snRNA termination is mediated, at least in part, by co-transcriptional cleavage and a 5'–3' exoribonuclease 2 (XRN2) torpedo mechanism. An alternative, or perhaps additional, mechanism for termination downstream of the mammalian U2 snRNA-encoding gene appears to involve a nucleosomal roadblock, the negative elongation factor (NELF), and the insulator protein CCCTC-binding factor (CTCF)⁶⁶. Unlike for Sen1 in yeast, senataxin does not seem to be needed at snRNA-encoding genes⁶⁰. For the unadenylated miRNA transcripts, the action of XRN2 following Drosha-mediated cleavage of miRNA precursors induces transcriptional termination⁶⁷. Termination mechanisms for the many other types of mammalian non-coding RNAs transcribed by Pol II⁶⁸ need to be investigated.

In summary, three mechanisms are thought to cause Pol II termination: conformational changes induced by binding of factors to the elongation complex; the collision of Rat1 or XRN2 with Pol II; and the action of a helicase, such as Sen1. Despite the accumulated evidence supporting the contributions of these different factors, the precise nature of changes occurring in the Pol II elongation complex, and how these are elicited by the factors discussed above, remains unresolved.

For example, one conundrum that has arisen is the role of Rat1. Rat1 degradation of the nascent transcript *in vitro*, and presumably its collision with Pol II, is not sufficient for release⁶⁹; nor is degradation by Xrn1, the cytoplasmic counterpart of Rat1, when the transcript is directed to the nucleus⁴⁰. Furthermore, 'rear-ending' of a paused Pol II by an actively transcribing one does not dislodge the stalled one, but rather promotes its moving beyond the pause site⁷⁰, suggesting that sheer force of collision is not enough. What then is needed to pry Pol II off its DNA template? Rati possesses an unusual tower domain that protrudes above the exoribonuclease active site and is longer than the equivalent region in Xrn1 (REFS 71,72). Degradation of the RNA may position such domains of Rati against the Pol II body in a way that promotes release. This event may also require the full constellation of processing factors, which were not present in the *in vitro* analysis mentioned above. Indeed, recruitment of cleavage and polyadenylation factors has been proposed as an alternative function for Rati in termination⁴⁰. If a helicase is the missing ingredient, then Sen1 cannot be the only source of this activity, as loss of Sen1 or senataxin function does not affect termination at all poly(A)-dependent genes^{51,59}.

Transcription termination in bacteria

The study of transcription termination in bacterial systems has been an active field of exploration for decades and may be a useful model for elucidating the molecular mechanisms that govern termination in eukaryotes. Many of the structural features and biochemical activities of bacterial RNA polymerases are conserved in higher eukaryotic RNA polymerases, and numerous bacterial regulatory factors have eukaryotic homologues or orthologues. Thus, information gleaned from the study of termination in these bacterial systems, which are relatively simpler than those in eukaryotes, may reveal general features of termination and important points of contact between polymerases and termination factors that are common to all cellular RNA polymerases. Some of the recent advances made in the field of bacterial transcription termination are highlighted below.

Rho-dependent termination.

A potentially paradigm-shifting report on termination has emphasized the role of allostery in mediating Rho-dependent transcription termination⁷³. Rho is an RNA-DNA helicase that serves as a general bacterial transcription termination factor⁵⁷. Rho binds preferentially to unstructured, C-rich nascent RNA and traverses RNA in the 5'–3' direction via RNA-dependent ATP hydrolysis, all the while threading RNA through its central cavity. A widely accepted model for Rho-dependent termination posits that Rho catches up to the elongation complex by translocating along the nascent transcript and, at certain sites, dissolves the elongation complex by pulling out the transcript. Contrary to this model, Epshtein *et al*⁷³ proposed that Rho loads directly onto RNA polymerase early in elongation and traps the elongation complex in an inactivated conformation at Rho-dependent termination sites. The observed dependence of Rho-mediated termination on functional RNA polymerase β' -lid and trigger loop domains led to the 'allosteric' model that Rho pushes against the lid to mediate hybrid melting (FIG. 3a). Pushing against the lid may also transmit an allosteric signal to the trigger loop, to which it is connected, thereby facilitating catalytic inactivation and eventual dissociation of the elongation complex.

Some evidence suggests that this allosteric model of bacterial transcription termination may have bearing on the mechanisms governing Pol II transcription termination. *Escherichia coli* Rho has been shown to dismantle Pol II elongation complexes assembled *in vitro*⁷⁴. Interestingly, neither Pol I nor Pol III demonstrated susceptibility to Rho-mediated termination, indicating that Rho activity was specific to Pol II. Given the structural conservation between bacterial RNA polymerase and eukaryotic Pol II, perhaps the Pol II Rpb1 lid serves as an effector domain contacted by Sen1 or Rati to elicit Pol II termination, similar to the way Rho mediates *E. coli* RNA polymerase termination (FIGS 3a,b).

Rho cofactors in termination.

In addition to the Rho termination factor, insights have been gained into the structure and function of two Rho cofactors, N utilization substance A (NusA) and NusG (an orthologue of the eukaryotic transcriptional regulator Spt5). NusA enhances intrinsic termination, whereas NusG enhances Rho-dependent termination^{75,76}. In a seemingly opposing manner, both Nus factors participate in *rnn*- and λ -antitermination complexes⁷⁷⁻⁷⁹. Recent studies have helped elucidate the mechanisms by which these factors function as terminators in some instances and antiterminators in others. Mutational analysis of NusA and chemically induced cleavage of NusA-bound RNA polymerase have led to proposed sites of interaction between NusA and RNA polymerase⁸⁰. The amino-terminal domain (NTD) of NusA possesses a concave hydrophobic core that is sufficient to stimulate pausing and termination through an interaction with the β -flap, which makes up part of the RNA exit channel of RNA polymerase, and the β' -dock domains (FIG. 3a). In addition to contacting the RNA exit site, the NusA NTD interacts with the nascent transcript and shields positions -17 to -30 from interaction with other macromolecules. The NusA-mediated stabilization of contacts between the β -flap and the emerging transcript is thought to produce a distal termination signal that is allosterically transmitted to the RNA polymerase active site, thereby constraining the catalytic residues and disfavoring elongation⁸¹. The λ Q protein, which forms part of the λ -antitermination complex, interacts with NusA in the vicinity of the β -flap, and this λ Q-NusA complex can also effectively shield and restrict access to the emerging transcript, thereby inhibiting Rho-dependent termination⁷⁹. Interaction with λ Q may thus mask the pausing- and termination-mediating structural features of NusA, as λ Q-mediated antipausing is decidedly dominant over NusA-mediated pausing. Another study suggests that λ Q protein bound to the β -flap may prevent the sflap from adopting a termination-competent conformation⁷⁹. Given the prominent role of the bacterial RNA polymerase β -flap as a major site of termination and antitermination regulation, the Pol II Rbp2 flap could participate in an analogous role in eukaryotic termination. This is an intriguing possibility as the site of RNA exit on Pol II is located in the vicinity of the last ordered residue of Rpb1, which marks the beginning of the linker to the CTD (FIGS 3b,c). In yeast, the CFIA and CPF processing factors and the Rati-associated protein Rtt103 interact directly with the CTD. Therefore, an expansion of the model for Pol II termination described above would be that degradation of the nascent chain by Rati brings these factors to the backside of Pol II, where they contact the Rpb2 flap domain and allosterically elicit termination.

Similar to NusA, NusG possesses an NTD that contacts RNA polymerase, as determined by NMR and mutational studies⁸³. The concave, hydrophobic surface of the NusG NTD is proposed to bind the complementary convex tip of the β' -clamp helices of RNA polymerase (FIG. 3a). Such a model is supported by an observed genetic interaction between NusG and the RNA polymerase clamp helices⁸⁴. Whereas the NTD is responsible for RNAP binding, the CTD of NusG interacts with Rho and thus stimulates Rho-dependent termination (FIG. 3a). When recruited into λ -antitermination complexes, the NusG CTD may be prevented from binding to Rho, thereby inhibiting Rho-mediated termination. Such masking is reminiscent of the λ Q-mediated modification of NusA termination activities. Another antiterminator, RfaH, is an operon-specific virulence factor that reduces Rho-mediated termination by competing with NusG for its binding site on the RNA polymerase β' -clamp helices^{85,86}. Thus the clamp helices, much like the flap domain, may be putative binding sites for regulators of transcription termination in eukaryotes. A comparison of the structures of *E. coli* RNA polymerase and *S. cerevisiae* Pol II is provided to highlight the relative positions of the regions contacted by bacterial transcription termination factors (FIG. 3).

Selecting a Pol II termination pathway

The CTD of the Rpb1 subunit is a binding surface for termination factors unique to eukaryotic Pol II and not found in bacterial or other RNA polymerases. Analysis of CTD phosphorylation dynamics across several model yeast genes revealed a dual gradient, with the ratio of Ser5-P to Ser2-P being high at the 5' end of genes and low at the 3' end⁸⁷ (FIG. 1b). Proteins involved in 'early' transcription events, such as RNA 5'-end capping, preferentially bind Ser5-P CTD⁸⁷, whereas proteins involved in 'late' events of Pol II transcription, such as RNA 3'-end processing, preferentially bind Ser2-P CTD^{88,89}. Ser7-P has more recently emerged as another major CTD modification and, like Ser5-P, it is enriched at the 5' ends of both protein-coding and non-coding genes^{62,90}. Thus far, the only known function for Ser7-P in Pol II transcription is in recruitment of the integrator complex to mammalian snRNA-encoding genes⁶².

Role of CTD phosphorylation in Pol II termination.

Pol II termination is facilitated when cis-acting elements in the nascent transcript are recognized by RNA-binding proteins that co-transcriptionally associate with the CTD (FIG. 2). In yeast, the type of CTD phosphorylation influences the mechanism of termination, and in metazoan cells it may prevent the use of strong poly(A) signals located near the promoter⁹¹. Based on the distance that Pol II has progressed from a transcription start site (TSS) and the associated change in CTD phosphorylation status, yeast Pol II becomes more prone to use either the Sen1-dependent or the poly(A)-dependent termination pathway⁹². Generally speaking, Sen1-dependent termination predominates at distances <1 kb from a TSS (typical for genes encoding snRNAs and snoRNAs), whereas poly(A)-dependent termination predominates at distances >1 kb from a TSS (typical for mRNA-encoding genes)^{51,92,93}. Nrd1, protein 1 of CFI (Pcf11; a component of the CFIA complex), and the Rat1-associated Rtt103 protein serve as 'readers' of the CTD code, with Nrd1 preferentially binding to Ser5-P⁹⁴ and Pcf11 and Rtt103 to Ser2-P CTD^{38,88}. In addition to the temporal recruitment of termination factors by the CTD, nascent RNA elements recruit some

termination factors independently of CTD phosphorylation status⁹². Therefore, the decision to terminate early or late during transcription is likely to be determined by kinetic competition between phosphorylation-specific CTD-binding proteins and sequence-specific RNA-binding proteins that associate with Pol II-elongation complexes²⁹.

A revised Pol II CTD code.

The dual gradient model of CTD phosphorylation was initially formulated using a small collection of model yeast genes, but until recently it was unknown whether the model applied generally across all Pol II-transcribed genes. Several recent genome-wide studies analysing the association of Pol II and termination factors with chromatin have provided a wealth of information that expands our understanding of the timing and specificity of these events^{24,95,96}. In general, the average global CTD phosphorylation pattern of most well-isolated and highly expressed long mRNAs is consistent with earlier results, namely that Ser5-P and Ser7-P are enriched at the 5' end of genes and Ser2-P is enriched at the 3' end (FIG. 4a). However, CTD phosphorylation patterns do not follow these canonical profiles at all genes. For example, a significant fraction of genes exhibit Ser2-P enrichment at the 5' end and/or Ser5-P enrichment at the 3' end, perhaps owing to the presence of CUTs and SUTs⁹⁶. The current model for the CTD code will probably need to be revised as the functional consequence of these alternative CTD phosphorylation patterns is investigated.

In addition to the canonical and noncanonical patterns of CTD phosphorylation observed at the beginning and end of genes, genome-wide studies have also provided a clearer picture of changes across the middle of genes. Ser7-P and Ser5-P overlap to some degree, but overall the Ser7-P profile is more variable than Ser5-P²⁴. Whereas Ser5-P exhibits a dramatic drop as Pol II progresses beyond the 5' end of a gene, Ser7-P remains present at higher levels and is retained all the way until transcription termination^{24,96} (FIG. 4a). The widespread occurrence of Ser7-P across coding regions suggests that it may contribute to efficient Pol II elongation, particularly in light of its enrichment at highly transcribed genes involved in ribosome biogenesis⁹⁶. In contrast to mRNA-encoding genes, the trend of Ser7-P and Ser5-P patterns overlaps more closely across non-coding RNA genes, and Ser2-P is under-represented even when gene size is taken into consideration⁹⁶ (FIG. 4b). An unexpected finding from the global analysis, given what had been deduced from the model genes, is that the ratio of Ser2-P to Ser5-P is not scaled to gene length and only increases within the first 500 bases of a transcription unit. Thus, the dual gradient model applies best to short genes²⁴. After the 500-base transition point, the ratio of Ser2-P to Ser5-P does not change substantially and thus would not provide a clear metric for Pol II position. Taken together, these data suggest that a combination of Ser7-P and Ser5-P enrichment and low Ser2-P serves as a signal for early Pol II transcription events, such as Sen1-dependent termination and the processing of short non-coding RNAs⁹⁶ (FIG. 2b). At later events during transcription, such as poly(A)-dependent termination and the processing of long mRNAs, Pol II position may be directed by a combination of other, unidentified CTD modifications and/or Pol II transit through termination signals.

Global localization of Pol II termination factors.

Genome-wide association studies of Pol II termination factors have confirmed some previously observed patterns from individual genes²⁴. Consistent with their functions in Sen1-dependent termination and poly(A)-dependent termination, respectively, Nrd1 is generally enriched at non-coding RNA genes (for example, snRNAs and snoRNAs, CUTs and SUTs) (FIG. 4b) and Pcf11 and Rat1 are enriched at mRNA 3' ends (FIG. 4a). Pcf11 also exhibits widespread recruitment to snoRNA-encoding genes along with Rat1 (FIG. 4b), which is somewhat surprising given that Rat1 exoribonuclease activity is not required for termination at several of the snoRNA-encoding genes tested⁹⁷. Overall, this pattern of recruitment supports the idea that the machinery for both Sen1-dependent and poly(A)-dependent termination is available to target Pol II during the elongation of all genes⁹⁷, and in fact may provide a way to ensure fail-safe termination^{43,44}.

The global genomic studies have also revealed new patterns of termination factor recruitment corresponding with distinct forms of CTD phosphorylation. The association of Nrd1 at non-coding RNA genes (for example snRNAs and snoRNAs, CUTs and SUTs) strongly colocalizes with Ser7-P²⁴ (FIG. 4b). This localization pattern suggests that, in addition to its previously demonstrated interaction with Ser5-P, Nrd1 may interact with Ser7-P. Precedence for recognition of a dual CTD mark comes from studies of proteins that bind Ser5-P and Ser2-P, such as the histone methyltransferase SET domain-containing 2 (Set2) that functions during elongation²⁸, and from protein complexes that bind Ser7-P and Ser2-P, such as the integrator complex⁹⁸. Pcf11 colocalizes with Nrd1 at regulatory non-coding RNAs located at the 5'-ends of some mRNA-encoding genes (for example, *HRP1*, IMP dehydrogenase 2 (*IMD2*), *NRD1* and *URA2*)²⁴. Pcf11 also colocalizes with Nrd1 across many snoRNA-encoding genes (FIG. 4b), which is somewhat surprising given that Pcf11 binds Ser2-P *in vitro*^{41,88} and snoRNA-encoding genes exhibit relatively meagre levels of Ser2-P⁹⁶ (FIG. 4b). However, this localization is entirely consistent with the requirement of Pcf11 for both poly(A)-dependent and Sen1-dependent termination⁹⁷.

The genome-wide occupancy of Pcf11 measured across mRNA-encoding genes does not correlate with Ser2-P^{24,95} (FIG. 4a). This apparent discrepancy could be explained by Ser2-P CTD being masked across genes *in vivo* or CTD-independent recruitment of Pcf11 by other 3'-end processing factors⁹⁵. Even though Ser2-P levels are lower at snoRNA-encoding genes relative to mRNA-encoding genes, their pattern at snoRNA-encoding genes correlates better with Pcf11 association²⁴ (FIG. 4b), suggesting that Ser2-P may be more important for Pcf11 recruitment at Sen1-dependent terminators than at poly(A)-dependent terminators. This finding is consistent with the fact that mutations in the Pcf11 CTD-interaction domain (CID) disrupt termination at snoRNA-encoding genes but not mRNA-encoding genes⁹⁷. Its also in line with the observation that loss of the Ser2-P kinase, CTD kinase subunit 1 (Ctk1; cyclin-dependent kinase 9 (CDK9) in mammals), has no effect on the termination of most yeast mRNA-encoding genes^{24,89}. It is important to note that the localization patterns of CTD phosphorylation and termination factors might also be affected by other factors. For example, by cooperative binding of two different proteins to neighbouring CTD repeats⁴¹, by the action of prolyl isomerases (for example, Ess1 and peptidyl-prolyl *cis-trans* isomerase NIMA-interacting 1 (PIN1)) that alter the presentation of phosphorylated Ser

residues^{28,99,100}, and by non-uniform phosphorylation patterns on the CTD, an idea that remains to be tested experimentally. Nevertheless, the global localization of Pol II CTD phosphorylation and termination factors reveals wider overlap than previously appreciated.

Conclusions and future directions

A strong argument can be made that the further Pol II advances through the transcription cycle, the less we understand about its underlying mechanism and regulation. At least part of this gap in knowledge is inherent to the fact that transcription becomes progressively more interconnected with other cellular processes as Pol II enters the later stages of RNA synthesis. Furthermore, the diversity of transcripts that Pol II synthesizes, and the importance of buffering its widespread genomic activity, has probably placed significant pressure on the cell to evolve alternative and redundant termination mechanisms. Over the past 25 years, significant progress has been made towards unravelling the intricate details of this fundamental process. Two dominant models for the molecular mechanism of termination at protein-coding genes have waxed and waned in the spotlight, eventually converging into a unified model. A distinct but overlapping pathway has emerged for yeast genes encoding non-coding RNA, and this is strongly reminiscent of the Rho-mediated transcription termination of bacterial RNA polymerase. Most recently, studies of individual model genes have been expanded to the genome-wide level, confirming some ideas and challenging others, as well as raising new important questions in the field.

Numerous elongation factors contribute to how well Pol II traverses a gene¹⁰¹ and in this Review we have not addressed how recruitment and/or loss of these elongation factors influence the likelihood of Pol II termination. Yeast elongation factors exit via a two-step 3' transition, during which some factors (for example, Paf1 and Burl) are released upstream of the poly(A) site and others (for example, Spt4 and Spt5) are released downstream^{95,102}. Paf1 has been implicated in mRNA poly(A) site selection and Sen1-dependent termination, perhaps through the recruitment of Pcf11 and Nrd1 (REF 103). However, the specific contribution of Paf1 and other such elongation factors to Pol II remains unclear. Recent work also supports a close physical juxtaposition of the 5' and 3' ends of genes, called gene-looping (BOX 1), and the implications of this linkage on termination will surely be the focus of future studies. Other areas meriting further investigation are the roles of chromatin modifications, nucleosome positioning and epigenetic modifications, which have all been implicated in poly(A) site selection and stalling of Pol II^{104–108}. Finally, the use of alternative poly(A) sites during cancer progression and in normal cell development is widespread and functionally important¹⁰⁹ but poorly understood mechanistically. How much of this is dictated by selection of the poly(A) site by the processing machinery, and how much by the decision of where to terminate? Hopefully, future work will lead to a more integrated model for termination that takes into account not only changes in Pol II but also its recent past and its immediate surroundings.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgements

Research in the laboratory of C.M. is supported by grants from the US National Institutes of Health National Institute of General Medical Sciences: award numbers K12GM074869 (J.N.K.), R01GM041752 (C.M.) and R01GM068887 (C.M.). We thank G. Meinke for assistance in preparing PyMOL images.

Biography

Jason N. Kuehner is a TEACRS postdoctoral fellow in the laboratory of Claire Moore at Tufts University School of Medicine, Boston, Massachusetts, USA. He received his B.A. in biochemistry and molecular biology from Cornell College, Mount Vernon, Iowa, USA, and conducted his Ph.D. research in cellular and molecular biology with David Brow at the University of Wisconsin-Madison, USA. He is currently investigating the coupling of eukaryotic RNA 3'-end processing with transcription termination and DNA repair.

Erika L. Pearson is a postdoctoral research associate in the Moore laboratory at Tufts University School of Medicine. She carried out her doctoral work with Dorothy Erie at the University of North Carolina at Chapel Hill, USA. Her current studies focus on the molecular mechanisms of transcription termination in eukaryotes.

Claire Moore has been a professor at Tufts University School of Medicine since 1986. She carried out her doctoral work with Jack Griffith at the University of North Carolina at Chapel Hill, and then did postdoctoral studies with Philip Sharp at the Massachusetts Institute of Technology, Cambridge, USA. Her laboratory studies polyadenylation in eukaryotes and the ways in which it interfaces with transcription, mRNA export and mRNA quality control.

Glossary

Cryptic unstable transcripts

Non-coding RNAs (~200–600 nucleotides long) discovered in yeast that are typically transcribed from intergenic regions of the genome (such as promoters) and are rapidly degraded by the exosome.

Stable untranslated transcripts

Non-coding RNAs discovered in yeast that are generally longer and more stable than cryptic unstable transcripts.

Promoter-proximal pausing

Halting of an early RNA polymerase elongation complex that remains competent to eventually resume transcription.

Genomic partitioning

Separation of adjacent DNA functional units from one another by transcription termination and/or DNA-binding proteins (such as chromatin) in order to prevent transcriptional interference.

Cleavage and polyadenylation specificity factor

A mammalian protein complex, containing an endo-ribonuclease and a poly(A) polymerase, that is required for efficient mRNA 3'-end processing and RNA polymerase II (Pol II) transcription termination. Homologous to yeast cleavage and polyadenylation factor, which is also required for efficient Pol II termination at small nuclear RNA-encoding and small nucleolar RNA-encoding genes.

Cleavage stimulatory factor

A mammalian protein complex that is required for efficient mRNA 3'-end processing and transcription termination. Homologous to yeast cleavage factor IA, which is also required for efficient RNA polymerase II termination at genes encoding small nuclear RNAs and small nucleolar RNAs.

Exosome

A protein complex that targets various types of RNA for degradation primarily via its 3'–5' exoribonuclease activity.

TRAMP

A polyadenylation complex that enhances exosome-mediated degradation of aberrant RNAs.

Drosha

A ribonuclease III enzyme that initiates processing of microRNAs.

Tower domain

A pronounced and conserved α -helix near the active site of the yeast nuclear 5'–3' exoribonuclease RNA-trafficking protein 1 (Rat1; Xrn2 in mammals) but not its cytoplasmic orthologue 5'–3' exoribonuclease 1 (Xrn1).

ChIP–chip

A technique that combines chromatin immunoprecipitation (ChIP) with microarray technology (chip) to investigate genome-wide protein-DNA interactions.

Prolyl isomerases

Enzymes that catalyse the interconversion of cis and trans isomers of peptide bonds with the amino acid Pro.

References

1. Lee TI & Young RA Transcription of eukaryotic protein-coding genes. *Annu. Rev. Genet* 34, 77–137 (2000). [PubMed: 11092823]
2. Espinosa JM The meaning of pausing. *Mol. Cell* 40, 507–508 (2010). [PubMed: 21095581]
3. Nechaev S. & Adelman K. Pol II waiting in the starting gates: regulating the transition from transcription initiation into productive elongation. *Biochim. Biophys. Acta* 1809, 34–45 (2011). [PubMed: 21081187]
4. Rosonina E, Kaneko S. & Manley JL Terminating the transcript: breaking up is hard to do. *Genes Dev.* 20, 1050–1056 (2006). [PubMed: 16651651]
5. Gilmour DS & Fan R. Derailing the locomotive: transcription termination. *J. Biol. Chem* 283, 661–664 (2008). [PubMed: 17998201]
6. Richard P. & Manley JL Transcription termination by nuclear RNA polymerases. *Genes Dev.* 23, 1247–1269 (2009). [PubMed: 19487567]

7. Merino E. & Yanofsky C. Transcription attenuation: a highly conserved regulatory strategy used by bacteria. *Trends Genet.* 21, 260–264 (2005). [PubMed: 15851059]
8. Naville M. & Gautheret D. Transcription attenuation in bacteria: theme and variations. *Brief Funct. Genomics* 9, 178–189 (2010). [PubMed: 20352660]
9. Dichtl B. Transcriptional ShortCUTs. *Mol. Cell* 31, 617–618 (2008). [PubMed: 18775320]
10. Kim KY & Levin DE Mpk 1 MAPK association with the Paf1 complex blocks Sen1-mediated premature transcription termination. *Cell* 144, 745–756 (2011). [PubMed: 21376235]
11. Jacquier A. The complex eukaryotic transcriptome: unexpected pervasive transcription and novel small RNAs. *Nature Rev. Genet* 10, 833–844 (2009). [PubMed: 19920851]
12. Shearwin KE, Callen BP & Egan JB Transcriptional interference — a crash course. *Trends Genet.* 21, 339–345 (2005). [PubMed: 15922833]
13. West S. & Proudfoot NJ Transcriptional termination enhances protein expression in human cells. *Mol. Cell* 33, 354–364 (2009). [PubMed: 19217409]
14. Mapendano CK, Lykke-Andersen S, Kjems J, Bertrand E & Jensen TH Crosstalk between mRNA 3' end processing and transcription initiation. *Mol. Cell* 40, 410–422 (2010). [PubMed: 21070967]
15. Ardehali MB & Lis JT Tracking rates of transcription and splicing *in vivo*. *Nature Struct. Mol. Biol* 16, 1123–1124 (2009). [PubMed: 19888309]
16. Kireeva ML, Komissarova N, Waugh DS & Kashlev M. The 8-nucleotide-long RNA:DNA hybrid is a primary stability determinant of the RNA polymerase II elongation complex. *J. Biol. Chem* 275, 6530–6536 (2000). [PubMed: 10692458]
17. Komissarova N, Becker J, Solter S, Kireeva M & Kashlev M. Shortening of RNA:DNA hybrid in the elongation complex of RNA polymerase is a prerequisite for transcription termination. *Mol. Cell* 10, 1151–1162 (2002). [PubMed: 12453422] References 16 and 17 implicate the RNA-DNA hybrid of the transcription elongation complex as a primary target of Pol II and bacterial RNA polymerase termination mechanisms.
18. Lykke-Andersen S. & Jensen TH Overlapping pathways dictate termination of RNA polymerase II transcription. *Biochimie* 89, 1177–1182 (2007). [PubMed: 17629387]
19. Rondon AG, Mischo HE & Proudfoot NJ Terminating transcription in yeast: whether to be a 'nerd' or a 'rat'. *Nature Struct. Mol. Biol* 15, 775–776 (2008). [PubMed: 18679429]
20. Logan J, Falck-Pedersen E, Darnell JE Jr & Shenk T. A poly(A) addition site and a downstream termination region are required for efficient cessation of transcription by RNA polymerase II in the mouse β maj-globin gene. *Proc. Natl Acad. Sci. USA* 84, 8306–8310 (1987). [PubMed: 3479794]
21. Whitelaw E. & Proudfoot N. α -thalassaemia caused by a poly(A) site mutation reveals that transcriptional termination is linked to 3' end processing in the human α 2 globin gene. *EMBO J.* 5, 2915–2922 (1986). [PubMed: 3024968]
22. Edwards-Gilbert G, Prescott J. & Falck-Pedersen E. 3' RNA processing efficiency plays a primary role in generating termination-competent RNA polymerase II elongation complexes. *Mol. Cell. Biol* 13, 3472–3480 (1993). [PubMed: 7684499]
23. Plant KE, Dye MJ, Lafaille C. & Proudfoot NJ Strong polyadenylation and weak pausing combine to cause efficient termination of transcription in the human γ -globin gene. *Mol. Cell. Biol* 25, 3276–3285 (2005). [PubMed: 15798211]
24. Kim H. et al. Gene-specific RNA polymerase II phosphorylation and the CTD code. *Nature Struct. Mol. Biol* 17, 1279–1286 (2010). [PubMed: 20835241] Provides genome-wide analysis of the dynamics of Pol II CTD phosphorylation and the recruitment of termination factors Pcf11, Nrd1 and Rat1.
25. Mandel CR, Bai Y. & Tong L. Protein factors in pre-mRNA 3'-end processing. *Cell. Mol. Life Sci* 65, 1099–1122 (2008). [PubMed: 18158581]
26. Millevoi S. & Vagner S. Molecular mechanisms of eukaryotic pre-mRNA 3' end processing regulation. *Nucleic Acids Res.* 38, 2757–2774 (2009). [PubMed: 20044349]
27. Shi Y. et al. Molecular architecture of the human pre-mRNA 3' processing complex. *Mol. Cell* 33, 365–376 (2009). [PubMed: 19217410]
28. Egloff S. & Murphy S. Cracking the RNA polymerase II CTD code. *Trends Genet.* 24, 280–288 (2008). [PubMed: 18457900]

29. Buratowski S. Progression through the RNA Polymerase II CTD Cycle. *Mol. Cell* 36, 541–546 (2009). [PubMed: 19941815]
30. Buratowski S. The CTD code. *Nature Struct. Biol* 10, 679–680 (2003). [PubMed: 12942140]
31. Gromak N, West S. & Proudfoot NJ Pause sites promote transcriptional termination of mammalian RNA polymerase II. *Mol. Cell. Biol* 26, 3986–3996 (2006). [PubMed: 16648491] Shows that a pause sequence promotes poly(A)-dependent termination *in vivo*, and the efficiency of termination is influenced by the strength of the poly(A) site and its proximity to the pause site.
32. Glover-Cutter K, Kim S, Espinosa J. & Bentley DL RNA polymerase II pauses and associates with pre-mRNA processing factors at both ends of genes. *Nature Struct. Mol. Biol* 15, 71–78 (2008). [PubMed: 18157150]
33. Park NJ, Tsao DC & Martinson HG The two steps of poly(A)-dependent termination, pausing and release, can be uncoupled by truncation of the RNA polymerase II carboxyl-terminal repeat domain. *Mol. Cell. Biol* 24, 4092–4103 (2004). [PubMed: 15121832]
34. Nag A, Narsinh K. & Martinson HG The poly(A)-dependent transcriptional pause is mediated by CPSF acting on the body of the polymerase. *Nature Struct. Mol. Biol* 14, 662–669 (2007). [PubMed: 17572685] This and other papers from the Martinson laboratory show that poly(A)-dependent termination of Pol II can be separated into two steps, pausing and release, that depend on interactions of the cleavage and polyadenylation machinery with the body of Pol II and the Pol II CTD.
35. Kazerouninia A, Ngo B. & Martinson HG Poly(A) signal-dependent degradation of unprocessed nascent transcripts accompanies poly(A) signal-dependent transcriptional pausing *in vitro*. *RNA* 16, 197–210 (2010). [PubMed: 19926725]
36. Alexander RD, Innocente SA, Barrass JD & Beggs JD Splicing-dependent RNA polymerase pausing in yeast. *Mol. Cell* 40, 582–593 (2010). [PubMed: 21095588]
37. Carrillo Oesterreich F, Preibisch S. & Neugebauer KM Global analysis of nascent RNA reveals transcriptional pausing in terminal exons. *Mol. Cell* 40, 571–581 (2010). [PubMed: 21095587]
38. Kim M. et al. The yeast Rat1 exonuclease promotes transcription termination by RNA polymerase II. *Nature* 432, 517–522 (2004). [PubMed: 15565157]
39. West S, Gromak N. & Proudfoot NJ Human 5′–3′ exonuclease Xrn2 promotes transcription termination at co-transcriptional cleavage sites. *Nature* 432, 522–525 (2004). [PubMed: 15565158] References 38 and 39 demonstrate that the 5′–3′ exoribonuclease Rat1 (XRN2 in mammals) is important for poly(A)-dependent termination and strengthen support for the torpedo model.
40. Luo W, Johnson AW & Bentley DL The role of Rat1 in coupling mRNA 3′-end processing to transcription termination: implications for a unified allosteric-torpedo model. *Genes Dev.* 20, 954–965 (2006). [PubMed: 16598041] Reveals that in addition to its exoribonuclease activity, Rat1 helps recruit mRNA 3′-end-processing factors. The authors propose a model for the termination mechanism that incorporates both allosteric and torpedo components.
41. Lunde BM et al. Cooperative interaction of transcription termination factors with the RNA polymerase II C-terminal domain. *Nature Struct. Mol. Biol* 17, 1195–1201 (2010).
42. Teixeira A. et al. Autocatalytic RNA cleavage in the human β -globin pre-mRNA promotes transcription termination. *Nature* 432, 526–530 (2004). [PubMed: 15565159]
43. Ghazal G. et al. Yeast RNase III triggers polyadenylation-independent transcription termination. *Mol. Cell* 36, 99–109 (2009). [PubMed: 19818713]
44. Rondón A, Mischo H, Kawauchi J. & Proudfoot N. Fail-safe transcriptional termination for protein-coding genes in *S. cerevisiae*. *Mol. Cell* 36, 88–98 (2009). [PubMed: 19818712]
45. Nabavi S. & Nazar RN Pac1 endonuclease and Dhp1p 5′–3′ exonuclease are required for U3 snoRNA termination in *Schizosaccharomyces pombe*. *FEBS Lett.* 584, 3436–3441 (2010). [PubMed: 20609363]
46. Connelly S. & Manley JL A functional mRNA polyadenylation signal is required for transcription termination by RNA polymerase II. *Genes Dev.* 2, 440–452 (1988). [PubMed: 2836265]
47. Houseley J. & Tollervey D. The many pathways of RNA degradation. *Cell* 136, 763–776 (2009). [PubMed: 19239894]

48. Kim HD, Choe J. & Seo YS The *sen1*⁺ gene of *Schizosaccharomyces pombe*, a homologue of budding yeast *SEN1*, encodes an RNA and DNA helicase. *Biochemistry* 38, 14697–14710 (1999). [PubMed: 10545196]
49. Steinmetz EJ & Brow DA Repression of gene expression by an exogenous sequence element acting in concert with a heterogeneous nuclear ribonucleoprotein-like protein, *Nrd1*, and the putative helicase *Sen1*. *Mol. Cell. Biol* 16, 6993–7003 (1996). [PubMed: 8943355]
50. Steinmetz EJ, Conrad NK, Brow DA & Corden JL RNA-binding protein *Nrd1* directs poly(A)-independent 3'-end formation of RNA polymerase II transcripts. *Nature* 413, 327–331 (2001). [PubMed: 11565036]
51. Steinmetz EJ et al. Genome-wide distribution of yeast RNA polymerase II and its control by *Sen1* helicase. *Mol. Cell* 24, 735–746 (2006). [PubMed: 17157256] This paper establishes *Sen1* as a general transcription termination factor in yeast for most snRNAs and snoRNAs and some short mRNA transcripts.
52. Ursic D, Chinchilla K, Finkel JS & Culbertson MR Multiple protein/protein and protein/RNA interactions suggest roles for yeast DNA/RNA helicase *Sen1p* in transcription, transcription-coupled DNA repair and RNA processing. *Nucleic Acids Res.* 32, 2441–2452 (2004). [PubMed: 15121901]
53. Finkel JS, Chinchilla K, Ursic D. & Culbertson MR *Sen 1 p* performs two genetically separable functions in transcription and processing of U5 small nuclear RNA in *Saccharomyces cerevisiae*. *Genetics* 184, 107–118 (2010). [PubMed: 19884310]
54. Mischo HE et al. Yeast *Sen1* helicase protects the genome from transcription-associated instability. *Mol. Cell* 41, 21–32 (2011). [PubMed: 21211720]
55. Arigo JT, Eyler DE, Carroll KL & Corden JL Termination of cryptic unstable transcripts is directed by yeast RNA-binding proteins *Nrd1* and *Nab3*. *Mol. Cell* 23, 841–851 (2006). [PubMed: 16973436]
56. Thiebaut M, Kisseleva-Romanova E, Rougemaille M, Boulay J. & Libri D. Transcription termination and nuclear degradation of cryptic unstable transcripts: a role for the *Nrd1-Nab3* pathway in genome surveillance. *Mol. Cell* 23, 853–864 (2006). [PubMed: 16973437]
57. Banerjee S, Chalissery J, Bandey I. & Sen R. Rho-dependent transcription termination: more questions than answers. *J. Microbiol* 44, 11–22 (2006). [PubMed: 16554712]
58. Kawauchi J, Mischo H, Braglia P, Rondon A. & Proudfoot NJ Budding yeast RNA polymerases I and II employ parallel mechanisms of transcriptional termination. *Genes Dev.* 22, 1082–1092 (2008). [PubMed: 18413718]
59. Banerjee A, Sammarco MC, Ditch S, Wang J. & Grabczyk E. A novel tandem reporter quantifies RNA polymerase II termination in mammalian cells. *PLoS ONE* 4, e6193 (2009).
60. Suraweera A. et al. Functional role for *senataxin*, defective in ataxia oculomotor apraxia type 2, in transcriptional regulation. *Hum. Mol. Genet* 18, 3384–3396 (2009). [PubMed: 19515850]
61. Matera AG, Terns RM & Terns MP Non-coding RNAs: lessons from the small nuclear and small nucleolar RNAs. *Nature Rev. Mol. Cell Biol* 8, 209–220 (2007). [PubMed: 17318225]
62. Egloff S. et al. Serine-7 of the RNA polymerase II CTD is specifically required for snRNA gene expression. *Science* 318, 1777–1779 (2007). [PubMed: 18079403] This study reveals that Ser7-P Pol II CTD helps recruit the integrator complex, which is required for human snRNA 3'-end processing.
63. Ezzeddine N. et al. A subset of *Drosophila* integrator proteins is essential for efficient U7 snRNA and spliceosomal snRNA 3' end formation. *Mol. Cell. Biol* 31, 328–341 (2011). [PubMed: 21078872]
64. Baillat D. et al. Integrator, a multiprotein mediator of small nuclear RNA processing, associates with the C-terminal repeat of RNA polymerase II. *Cell* 123, 265–276 (2005). [PubMed: 16239144]
65. Dominski Z, Yang X-C, Purdy M, Wagner EJ & Marzluff W. F A CPSF-73 homologue is required for cell cycle progression but not cell growth and interacts with a protein having features of CPSF-100. *Mol. Cell. Biol* 25, 1489–1500 (2005). [PubMed: 15684398]
66. Egloff S, Al-Rawaf H, O'Reilly D & Murphy S. Chromatin structure is implicated in “late” elongation checkpoints on the U2 snRNA and β -actin genes. *Mol. Cell. Biol* 29, 4002–4013 (2009). [PubMed: 19451231]

67. Ballarino M. et al. Coupled RNA processing and transcription of intergenic primary microRNAs. *Mol. Cell. Biol* 29, 5632–5638 (2009). [PubMed: 19667074]
68. Carninci P. Molecular biology: the long and short of RNAs. *Nature* 457, 974–975 (2009).
69. Dengl S. & Cramer P. Torpedo nuclease Rat1 is insufficient to terminate RNA polymerase II *in vitro*. *J. Biol. Chem* 284, 21270–21279 (2009). [PubMed: 19535338]
70. Saeki H. & Svejstrup JQ Stability, flexibility, and dynamic interactions of colliding RNA polymerase II elongation complexes. *Mol. Cell* 35, 191–205 (2009). [PubMed: 19647516]
71. Xiang S. et al. Structure and function of the 5′–3′ exoribonuclease Rat 1 and its activating partner Rai 1. *Nature* 458, 784–788 (2009). [PubMed: 19194460]
72. Chang JH, Xiang S, Xiang K, Manley JL & Tong L. Structural and biochemical studies of the 5′–3′ exoribonuclease Xrn1. *Nature Struct. Mol. Biol* 18, 270–276 (2011). [PubMed: 21297639]
73. Epshtein V, Dutta D, Wade J & Nudler E. An allosteric mechanism of Rho-dependent transcription termination. *Nature* 463, 245–249 (2010). [PubMed: 20075920] Demonstrates that the Rho termination factor associates directly with *E. coli* RNA polymerase and promotes termination by inducing an allosteric rearrangement of the rna polymerase active site. Transduction of the termination signal is dependent on the lid and trigger loop domains of the RNA polymerase β' -subunit.
74. Lang WH, Platt T & Reeder RH Escherichia coli Rho factor induces release of yeast RNA polymerase II but not polymerase I or III. *Proc. Natl Acad. Sci. USA* 95, 4900–4905 (1998). [PubMed: 9560200]
75. Schmidt MC & Chamberlin MJ nusA protein of Escherichia coli is an efficient transcription termination factor for certain terminator sites. *J. Mol. Biol* 195, 809–818 (1987). [PubMed: 2821282]
76. Sullivan SL & Gottesman ME Requirement for E. coli NusG protein in factor-dependent transcription termination. *Cell* 68, 989–994 (1992). [PubMed: 1547498]
77. Mason SW, Li J & Greenblatt J. Host factor requirements for processive antitermination of transcription and suppression of pausing by the N protein of bacteriophage λ . *J. Biol. Chem* 267, 19418–19426 (1992). [PubMed: 1388170]
78. Torres M, Condon C, Balada JM, Squires C. & Squires CL Ribosomal protein S4 is a transcription factor with properties remarkably similar to NusA, a protein involved in both non-ribosomal and ribosomal RNA antitermination. *EMBO J.* 20, 3811–3820 (2001). [PubMed: 11447122]
79. Shankar S, Hatoum A. & Roberts JW A transcription antiterminator constructs a NusA-dependent shield to the emerging transcript. *Mol. Cell* 27, 914–927 (2007). [PubMed: 17889665]
80. Ha KS, Touloukhonov I, Vassilyev DG & Landick R. The NusA N-terminal domain is necessary and sufficient for enhancement of transcriptional pausing via interaction with the RNA exit channel of RNA polymerase. *J. Mol. Biol* 401, 708–725 (2010). [PubMed: 20600118] Findings from this study show that interaction of the NusA termination factor with regions of bacterial RNA polymerase near the RNA exit channel (such as the β -flap and β' -dock) stimulates pausing and release.
81. Touloukhonov I, Artsimovitch I. & Landick R. Allosteric control of RNA polymerase by a site that contacts nascent RNA hairpins. *Science* 292, 730–733 (2001). [PubMed: 11326100]
82. Deighan P, Diez CM, Leibman M, Hochschild A. & Nickels BE The bacteriophage λ Q antiterminator protein contacts the β -flap domain of RNA polymerase. *Proc. Natl Acad. Sci. USA* 105, 15305–15310 (2008). [PubMed: 18832144]
83. Mooney RA, Schweimer K, Rosch P, Gottesman M & Landick R. Two structurally independent domains of E. coli NusG create regulatory plasticity via distinct interactions with RNA polymerase and regulators. *J. Mol. Biol* 391, 341–358 (2009). [PubMed: 19500594] Reveals how interactions with two separate protein domains of NusG contribute to its RNA polymerase termination and antitermination activities. The NusG NTD contacts the RNA polymerase β' -clamp helices while its CTD binds Rho or other transcriptional regulators.
84. Nickels BE Genetic assays to define and characterize protein-protein interactions involved in gene regulation. *Methods* 47, 53–62 (2009). [PubMed: 18952173]
85. Belogurov GA, Mooney RA, Svetlov V, Landick R & Artsimovitch I. Functional specialization of transcription elongation factors. *EMBO J.* 28, 112–122 (2009). [PubMed: 19096362]

86. Belogurov GA, Sevostyanova A, Svetlov V. & Artsimovitch I. Functional regions of the N-terminal domain of the antiterminator RfaH. *Mol. Microbiol* 76, 286–301 (2010). [PubMed: 20132437]
87. Komarnitsky P, Cho EJ & Buratowski S. Different phosphorylated forms of RNA polymerase II and associated mRNA processing factors during transcription. *Genes Dev.* 14, 2452–2460 (2000). [PubMed: 11018013] Shows that dynamic phosphorylation of the Pol II CTD contributes to differential recruitment of mRNA processing factors, a discovery that forms the basis of the CTD code hypothesis.
88. Licatalosi DD et al. Functional interaction of yeast pre-mRNA 3' end processing factors with RNA polymerase II. *Mol. Cell* 9, 1101–1111 (2002). [PubMed: 12049745]
89. Ahn SH, Kim M. & Buratowski S. Phosphorylation of serine 2 within the RNA polymerase II C-terminal domain couples transcription and 3' end processing. *Mol. Cell* 13, 67–76 (2004). [PubMed: 14731395]
90. Chapman RD et al. Transcribing RNA polymerase II is phosphorylated at CTD residue serine-7. *Science* 318, 1780–1782 (2007). [PubMed: 18079404] Identifies dynamic phosphorylation of the Pol II CTD at Ser7 as a new component of the CTD code.
91. Guo J, Garrett M, Micklem G & Brogna S. Poly(A) signals located near the 5' end of genes are silenced by a general mechanism that prevents premature 3'-end processing. *Mol. Cell. Biol* 31, 639–651 (2011). [PubMed: 21135120]
92. Gudipati RK, Villa T, Boulay J. & Libri D. Phosphorylation of the RNA polymerase II C-terminal domain dictates transcription termination choice. *Nature Struct. Mol. Biol* 15, 786–794 (2008). [PubMed: 18660821] Shows that the selection of the poly(A)-dependent versus Sen1-dependent termination pathway is influenced by the phosphorylation status of the Pol II CTD, which is in turn influenced by the distance that Pol II travels from the transcription start site.
93. Jenks MH, O'Rourke TW & Reines D. Properties of an intergenic terminator and start site switch that regulate IMD2 transcription in yeast. *Mol. Cell. Biol* 28, 3883–3893 (2008). [PubMed: 18426909]
94. Vasiljeva L, Kim M, Mutschler H, Buratowski S. & Meinhart A. The Nrd 1-Nab3-Sen 1 termination complex interacts with the Ser5-phosphorylated RNA polymerase II C-terminal domain. *Nature Struct. Mol. Biol* 15, 795–804 (2008). [PubMed: 18660819]
95. Mayer A. et al. Uniform transitions of the general RNA polymerase II transcription complex. *Nature Struct. Mol. Biol* 17, 1272–1278 (2010). [PubMed: 20818391]
96. Tietjen JR et al. Chemical-genomic dissection of the CTD code. *Nature Struct. Mol. Biol* 17, 1154–1161 (2010). [PubMed: 20802488] References 95 and 96 provide genome-wide analyses of the dynamics of Pol II CTD-phosphorylation and identify gene-specific patterns of CTD marks or transcription factor recruitment, respectively.
97. Kim M. et al. Distinct pathways for snoRNA and mRNA termination. *Mol. Cell* 24, 723–734 (2006). [PubMed: 17157255] Reveals that many poly(A)-dependent and Sen1-dependent termination factors can be localized to both mRNA and snoRNA-encoding genes, but their requirements for termination are gene-specific.
98. Egloff S. et al. The integrator complex recognizes a new double mark on the RNA polymerase II carboxyl-terminal domain. *J. Biol. Chem* 285, 20564–20569 (2010). [PubMed: 20457598]
99. Singh N. et al. The Ess 1 prolyl isomerase is required for transcription termination of small noncoding RNAs via the Nrd1 pathway. *Mol. Cell* 36, 255–266 (2009). [PubMed: 19854134]
100. Werner-Allen JW et al. cis-proline-mediated Ser(P)⁵ dephosphorylation by the RNA polymerase II C-terminal domain phosphatase Ssu72. *J. Biol. Chem* 286, 5717–5726 (2011). [PubMed: 21159777]
101. Selth LA, Sigurdsson S. & Svejstrup JQ Transcript Elongation by RNA Polymerase II. *Annu. Rev. Biochem* 79, 271–293 (2010). [PubMed: 20367031]
102. Kim M, Ahn SH, Krogan NJ, Greenblatt JF & Buratowski S. Transitions in RNA polymerase II elongation complexes at the 3' ends of genes. *EMBO J.* 23, 354–364 (2004). [PubMed: 14739930]
103. Jaehning JA The Paf 1 complex: platform or player in RNA polymerase II transcription? *Biochim. Biophys. Acta* 1799, 379–388 (2010). [PubMed: 20060942]

104. Alén C. et al. A role for chromatin remodeling in transcriptional termination by RNA polymerase II. *Mol. Cell* 10, 1441–1452 (2002). [PubMed: 12504018]
105. Wood AJ et al. Regulation of alternative polyadenylation by genomic imprinting. *Genes Dev.* 22, 1141–1146 (2008). [PubMed: 18451104]
106. Spies N, Nielsen CB, Padgett RA & Burge CB Biased chromatin signatures around polyadenylation sites and exons. *Mol. Cell* 36, 245–254 (2009). [PubMed: 19854133]
107. Alló M. & Kornblihtt AR Gene silencing: small RNAs control RNA polymerase II elongation. *Curr. Biol* 20, R704–R707 (2010). [PubMed: 20833310]
108. Fan X. et al. Nucleosome depletion at yeast terminators is not intrinsic and can occur by a transcriptional mechanism linked to 3'-end formation. *Proc. Natl Acad. Sci. USA* 107, 17945–17950 (2010). [PubMed: 20921369]
109. Mayr C. & Bartel DP Widespread shortening of 3'UTRs by alternative cleavage and polyadenylation activates oncogenes in cancer cells. *Cell* 138, 673–684 (2009). [PubMed: 19703394]
110. Calvo O. & Manley JL Strange bedfellows: polyadenylation factors at the promoter. *Genes Dev.* 17, 1321–1327 (2003). [PubMed: 12782649]
111. Venters BJ & Pugh BF How eukaryotic genes are transcribed. *Crit. Rev. Biochem. Mol. Biol* 44, 117–141 (2009). [PubMed: 19514890]
112. Hampsey M, Singh BN, Ansari A, Lainé J-P & Krishnamurthy S. Control of eukaryotic gene expression: gene loops and transcriptional memory. *Adv. Enzyme Regul* 29 10 2010 (doi: 10.1016/j.advenzreg.2010.10.001).
113. El Kaderi B, Medler S, Raghunayakula S & Ansari A. Gene looping is conferred by activator-dependent interaction of transcription initiation and termination machineries. *J. Biol. Chem* 284, 25015–25025 (2009). [PubMed: 19602510]
114. Wang Y, Fairley JA & Roberts SGE Phosphorylation of TFIIB links transcription initiation and termination. *Curr. Biol* 20, 548–553 (2010). [PubMed: 20226668]
115. Moore MJ & Proudfoot NJ Pre-mRNA processing reaches back to transcription and ahead to translation. *Cell* 136, 688–700 (2009). [PubMed: 19239889]
116. Lykke-Andersen S, Mapendano CK & Jensen TH An ending is a new beginning: transcription termination supports re-initiation. *Cell Cycle* 10, 863–865 (2011). [PubMed: 21325895]
117. Glover-Cutter K. et al. TFIIF-associated Cdk7 kinase functions in phosphorylation of C-terminal domain Ser7 residues, promoter-proximal pausing, and termination by RNA polymerase II. *Mol. Cell. Biol* 29, 5455–5464 (2009). [PubMed: 19667075]
118. Jimeno-González S, Haaning LL, Malagon F & Jensen TH The yeast 5'-3' exonuclease Rat1p functions during transcription elongation by RNA polymerase II. *Mol. Cell* 37, 580–587 (2010). [PubMed: 20188675]
119. Opalka N. et al. Complete structural model of Escherichia coli RNA polymerase from a hybrid approach. *PLoS Biol.* 8, e1000483 (2010).
120. Cramer P, Bushnell DA & Kornberg RD Structural basis of transcription: RNA polymerase II at 2.8 angstrom resolution. *Science* 292, 1863–1876 (2001). [PubMed: 11313498]
121. Kettenberger H, Armache KJ & Cramer P. Complete RNA polymerase II elongation complex structure and its interactions with NTP and TFIIS. *Mol. Cell* 16, 955–965 (2004). [PubMed: 15610738]
122. Birse CE, Minvielle-Sebastia L, Lee BA, Keller W. & Proudfoot NJ Coupling termination of transcription to messenger RNA maturation in yeast. *Science* 280, 298–301 (1998). [PubMed: 9535662]
123. Sadowski M, Dichtl B, Hübner W. & Keller W. Independent functions of yeast Pcf11p in pre-mRNA 3' end processing and in transcription termination. *EMBO J.* 22, 2167–2177 (2003). [PubMed: 12727883]
124. Zhang Z, Fu J. & Gilmour DS CTD-dependent dismantling of the RNA polymerase II elongation complex by the pre-mRNA 3'-end processing factor, Pcf11. *Genes Dev.* 19, 1572–1580 (2005). [PubMed: 15998810]
125. Dichtl B. et al. Yhh1p/Cft1p directly links poly(A) site recognition and RNA polymerase II transcription termination. *EMBO J.* 21, 4125–4135 (2002). [PubMed: 12145212]

126. Garas M, Dichtl B. & Keller W. The role of the putative 3' end processing endonuclease Ysh 1p in mRNA and snoRNA synthesis. *RNA* 14, 2671–2684 (2008). [PubMed: 18971324]
127. Nedeia E. et al. Organization and function of APT, a subcomplex of the yeast cleavage and polyadenylation factor involved in the formation of mRNA and small nucleolar RNA 3'-ends. *J. Biol. Chem* 278, 33000–33010 (2003). [PubMed: 12819204]
128. Nedeia E. et al. The Glc7 phosphatase subunit of the cleavage and polyadenylation factor is essential for transcription termination on snoRNA genes. *Mol. Cell* 29, 577–587 (2008). [PubMed: 18342605]
129. Ghazy MA, He X, Singh BN, Hampsey M. & Moore C. The essential N terminus of the Pta 1 scaffold protein is required for snoRNA transcription termination and Ssu72 function but is dispensable for pre-mRNA 3'-end processing. *Mol. Cell. Biol* 29, 2296–2307 (2009). [PubMed: 19188448]
130. Ganem C. et al. Ssu72 is a phosphatase essential for transcription termination of snoRNAs and specific mRNAs in yeast. *EMBO J.* 22, 1588–1598 (2003). [PubMed: 12660165]
131. Steinmetz EJ & Brow DA Ssu72 protein mediates both poly(A)-coupled and poly(A)-independent termination of RNA polymerase II transcription. *Mol. Cell. Biol* 23, 6339–6349 (2003). [PubMed: 12944462]
132. Xue Y. et al. *Saccharomyces cerevisiae* RAI1 (YGL246c) is homologous to human DOM3Z and encodes a protein that binds the nuclear exoribonuclease Rat1p. *Mol. Cell. Biol* 20, 4006–4015 (2000). [PubMed: 10805743]
133. Kaneko S, Rozenblatt-Rosen O, Meyerson M. & Manley JL The multifunctional protein p54nrb/PSF recruits the exonuclease XRN2 to facilitate pre-mRNA 3' processing and transcription termination. *Genes Dev.* 21, 1779–1789 (2007). [PubMed: 17639083]
134. Arigo JT, Carroll KL, Ames JM & Corden JL Regulation of yeast NRD1 expression by premature transcription termination. *Mol. Cell* 21, 641–651 (2006). [PubMed: 16507362]
135. Barillà D, Lee BA & Proudfoot NJ Cleavage/polyadenylation factor IA associates with the carboxyl-terminal domain of RNA polymerase II in *Saccharomyces cerevisiae*. *Proc. Natl Acad. Sci. USA* 98, 445–450 (2001). [PubMed: 11149954]
136. McCracken S. et al. The C-terminal domain of RNA polymerase II couples mRNA processing to transcription. *Nature* 385, 357–361 (1997). [PubMed: 9002523]
137. Steinmetz EJ, Ng SB, Cloute JP & Brow DA cis- and trans-acting determinants of transcription termination by yeast RNA polymerase II. *Mol. Cell. Biol* 26, 2688–2696 (2006). [PubMed: 16537912]
138. Mueller CL, Porter SE, Hoffman MG & Jaehning JA The Paf 1 complex has functions independent of actively transcribing RNA polymerase II. *Mol. Cell* 14, 447–456 (2004). [PubMed: 15149594]
139. Sheldon KE, Mauger DM & Arndt KM A requirement for the *Saccharomyces cerevisiae* Paf 1 complex in snoRNA 3' end formation. *Mol. Cell* 20, 225–236 (2005). [PubMed: 16246725]

Box 1 |**The end is the beginning is the end**

Perhaps owing to their seemingly distal position from one another, the transcriptional events that take place at the beginning and end of a gene are often studied independently from one another.

However, RNA polymerase II (Pol II) initiation factors and the 3'-end processing and termination machinery are more intertwined than one might expect¹¹⁰, and several recent papers provide new insight into the biological significance of this linkage.

Transcription initiation factor IIB (TFIIB) is a general transcription factor that directs assembly of the pre-initiation complex scaffold at the promoter¹¹¹. In yeast, TFIIB also interacts with the cleavage and polyadenylation factor (CPF) 3'-end processing complex, which contributes to the juxtaposition of promoter and terminator DNA through a process known as gene looping¹¹² (see the figure). New evidence reveals that gene looping in yeast also requires the interaction of TFIIB with the cleavage factor IA (CFIA) 3'-end processing factor, a linkage that is dependent on a transcriptional activator¹¹³. This interaction is conserved in the mammalian system, in which it is regulated by TFIIB phosphorylation and necessary for productive elongation¹¹⁴, and this is consistent with a model in which gene loops promote Pol II reinitiation^{112,115,116}.

TFIIH is a general transcription factor that facilitates promoter clearance, at least in part, through the action of its Kin28 subunit (cyclin-dependent kinase 7 (CDK7) in mammals), a kinase that phosphorylates the Pol II carboxy-terminal domain (CTD) at Ser₅ and Ser₇ (REF. 111). TFIIH activity was thought to be restricted to the promoter, but a recent report reveals that CDK7 and the core subunit p62 also localize to coding regions and the 3' ends of genes¹¹⁷. Furthermore, inhibition of CDK7 causes delays in both promoter-proximal pausing and transcription termination.

The recruitment of RNA-trafficking protein 1 (Rat1; XRN2 in mammals), the exoribonuclease that helps trigger Pol II termination^{38,39}, peaks at the 3' end of genes. However, Rat1 can also be detected at gene promoters and coding regions. A new report reveals a function for Rat1 at these more upstream positions, namely to terminate Pol II molecules engaged in the production of uncapped RNA¹¹⁸. Overall, the connections highlighted above reveal that template DNA and its associated transcription factors are more versatile than previously appreciated, and this flexibility provides additional avenues for control of both Pol II activity and RNA quality.

Online 'at-a-glance' Summary

- RNA polymerase II (Pol II) transcribes all eukaryotic protein-coding genes and most non-coding RNA genes. The final step of transcription is termination, which leads to the release of Pol II and RNA from the DNA template through a poorly defined mechanism.
- Transcription termination serves many vital functions in the cell, such as preventing RNA polymerase interference with neighbouring DNA elements, recycling RNA polymerase, promoting RNA 3'-end processing, and regulating gene expression via premature termination of transcription (that is, attenuation).
- Termination can be elicited through different pathways depending on the phosphorylation status of the Pol II carboxy-terminal domain (CTD) and the presence of various RNA signals and termination factors. Two of the best-studied termination pathways are the poly(A)-dependent pathway and Sen1-dependent pathway, which are connected to RNA 3'-end processing events for mRNAs and non-coding RNAs, respectively.
- Three mechanisms are proposed to cause Pol II termination: conformational changes induced by binding of factors to Pol II; collision of an exoribonuclease with Pol II; and/or disruption of the Pol II active site hybrid by an RNA-DNA helicase. However, these molecular models have thus far remained insufficient to fully explain how termination occurs.
- Pol II is similar both structurally and biochemically to bacterial RNA polymerase, suggesting that there may be some general features of termination that are common to all cellular RNA polymerases. Recent studies investigating the requirements for bacterial termination implicate several regions of Pol II as putative termination effector domains, including the lid, trigger loop, clamp helices, dock and flap.
- The phosphorylation status of the Pol II CTD residues Ser₇, Ser₅ and Ser₂ is dynamic across the length of a gene. Genome-wide localization studies suggest that a combination of high Ser₇-P and Ser₅-P and low Ser₂-P at promoter-proximal positions may serve as a signal to trigger Sen1-dependent termination.
- Genome-wide localization of protein 1 of CFI (Pcf11), Nrd1, and RNA-trafficking protein 1 (Rat1) reveals extensive overlap of these termination factors along both protein-coding and non-coding RNA genes. This pattern is consistent with the idea that the machinery for Sen1-dependent termination and poly(A)-dependent termination is broadly available to target Pol II during transcription of most genes, and in fact may provide a way to ensure fail-safe termination.

Figure 1 | Pol II transcription is coordinated with distinct patterns of C-terminal domain phosphorylation.

a | Initiation: RNA polymerase II (Pol II) is recruited to a gene promoter by transcription factors, the DNA is melted to expose the template strand, and the first few nucleotides of RNA are synthesized. Elongation: a full-length RNA–DNA hybrid is formed (~8–9 bp) and Pol II proceeds to extend the transcript. Termination: Pol II ceases RNA synthesis and becomes termination-prone (indicated by its change in colour from green to yellow), and both Pol II and the nascent RNA are released from the template. As shown, destabilization of the RNA–DNA hybrid in the Pol II active site is likely to be a key feature in termination. Protein factors involved in elongation, RNA processing and termination (shown as yellow, blue and orange ovals, respectively) co-transcriptionally associate with the Pol II carboxy-terminal domain (CTD). **b** | The phosphorylation status of the CTD heptad repeats (Tyr₁-Ser₂-Pro₃-Thr₄-Ser₅-Pro₆-Ser₇) changes as Pol II progresses through a gene^{28,29}. Hypophosphorylated Pol II is recruited into the pre-initiation complexes and it is phosphorylated on Ser5 by the transcription initiation factor IIH (TFIIH) kinase Kin28 (cyclin-dependent kinase 7 (CDK7) in mammals) during initiation and on Ser2 by CTD kinase subunit 1 (Ctk1; CDK9 in mammals) during elongation. The action of these kinases, combined with their opposing phosphatases (suppressor of Sua7 2 (Ssu72) and regulator of transcription 1 (Rtr1) for Ser5-P and Fcp1 for Ser2-P), sets up a dual gradient of CTD modification, with Ser5-P and Ser2-P being more prevalent towards the 5' end and the 3' end of the gene, respectively. Several other kinases and phosphatases contribute to this gradient but are not discussed for simplicity. Each phosphorylation shown on the CTD represents a single heptad repeat (not all repeats are shown) with the general phosphorylation patterns indicated.

Figure 2 | Factors involved in poly(A)-dependent and Sen1-dependent termination.

Counterparts of termination factors in yeast and humans are shown in the same colour, and known interactions between RNA, RNA polymerase II (Pol II) and other factors are indicated by direct contacts. Pol II carboxy-terminal domain (CTD) phosphorylation dynamics are indicated as in FIG. 1b, with Ser2-P being higher than Ser5-P in regions of poly(A)-dependent termination, and the reverse pattern being observed in regions of Sen1-dependent termination. **a** | In poly(A)-dependent termination in yeast, the 5′–3′ exoribonuclease RNA-trafficking protein 1 (Rat1; XRN2 in mammals) is recruited to Pol II via proteins that interact with phosphorylated Ser2 in the CTD (such as regulator of Ty1 transposition 103 (Rtt103)) and poly(A) site RNA elements (such as the indicated A-rich and U-rich sequences). Rat1 degrades the downstream RNA (dashed light blue line) that results from the 3′-end processing cleavage event (scissors), which may result in disruption of the Pol II active site hybrid that is representative of the ‘torpedo’ model. In addition to contacting the CTD, cleavage and polyadenylation factor (CPF; homologous to human cleavage and polyadenylation specificity factor (CPSF)) may also interact with the body of Pol II through its suppressor of Sua7 2 (Ssu72) subunit. Optimal association of Rat1 with chromatin requires cleavage factor IA (CFIA; homologous to human cleavage stimulatory factor (CstF)), but direct contacts with CFIA have not been reported. **b** | In Sen1-dependent termination in yeast, the mechanism that applies to most non-coding RNAs, Sen1 is recruited to Pol II via proteins that interact with Pol II Ser5-P CTD (such as Nrd1) and

specific RNA elements (such as GUAA repeats). Sen1 may unwind the Pol II active site hybrid via its helicase activity. c | In poly(A)-dependent termination in humans, pausing of human Pol II is induced when CPSF bound to the body of Pol II recognizes the AAUAAA signal sequence that emerges in the nascent transcript (step **1**). Upon exposure of the GU-rich binding site, CstF dislodges CPSF (step **2**). Following cleavage at the poly(A) site, 5'–3' exoribonuclease 2 (XRN2) degrades the downstream RNA product, which may displace Pol II as described above for Rat1 (step **3**). CFII_m, mammalian CFII; DOM3Z, DOM-3 homologue Z; Nab3, nuclear polyadenylated RNA-binding 3; Rai1, Rat1-interacting 1.

Figure 3 |. Comparison of *E. coli* RNA polymerase and *S. cerevisiae* Pol II structures.

A summary of the putative sites on bacterial RNA polymerase that are contacted by Rho, N utilization substance A (NusA) and NusG, and their corresponding regions in yeast RNA polymerase II (Pol II), are shown. **a,b** | A molecular model of *Escherichia coli* RNA polymerase¹¹⁹ (**a**) and a crystal structure model of *Saccharomyces cerevisiae* Pol II¹²⁰ (**b**) are depicted in cartoon rendering (β' -subunit (Rpb1 in *S. cerevisiae*), pale teal; β -subunit (Rpb2 in *S. cerevisiae*), light pink; other subunits, wheat; active site, red). The key sites of interaction on *E. coli* RNA polymerase are highlighted in space-filled rendering (β -flap, yellow; β' -clamp helices, teal; β' -lid, violet; β' -dock, orange), as are the relative sites on Pol II. Note that only the flanking amino-terminal and carboxy-terminal residues of the Pol II Rpb2 flap are shown as the loop is too disordered to be depicted here. **c** | Crystal structure model of the *S. cerevisiae* Pol II elongation complex¹²¹ depicted as detailed for *E. coli* RNA polymerase in (**a**), but rotated to show the trigger loop (highlighted in blue in space-filled rendering). The template DNA (green) and the nascent transcript (red) are also shown, to emphasize the close proximity of the features detailed in (**a**) to the RNA exit path. For simplicity, the Rpb4 and Rpb7 subunits of the Pol II elongation complex are hidden. The structures in this figure were created with PyMOL (Schrödinger) using Protein Data Bank files [3LU0](#) for RNA polymerase and [1I3Q](#) and [1Y1W](#) for Pol II.

Figure 4 |. Genome-wide localization of yeast Pol II CTD phosphorylations and termination factors.

The localization of RNA polymerase II (Pol II) phospho-carboxy-terminal domain (CTD) isoforms (left) and protein 1 of CFI (Pcf11), RNA-trafficking protein 1 (Rat1) and Nrd1 (right) were mapped across the entire yeast genome by ChIP–chip. Average distributions for highly expressed long mRNA-encoding genes (>2,000 bases, 128 genes) (**a**) and short small nucleolar RNA (snoRNA)-encoding genes (<700 bases, 31 genes) (**b**) are shown.

Transcription units for mRNA-encoding genes (transcription start site (TSS) to poly(A) site)

and snoRNA-encoding genes (TSS to mature 3' end), indicated by arrows, are divided into 10 equal intervals and flanked with 1 kb of 5' and 3' sequence. Images are modified, with permission, from REF. 24.

Table 1 |

Factors involved in Pol II termination*

Yeast complex	Yeast protein	Human homologue?	Protein function	Putative role in termination	Refs
CFIA	Pcf11	PCF11	Binds Pol II Ser2-P CTD, scaffolding protein	Poly(A)-dependent Promotes RNA cleavage and Rat1 recruitment, disrupts Pol II hybrid by bridging CTD and RNA	Sen1-dependent Disrupts Pol II hybrid by bridging CTD and RNA
					40,97, 122–124
CPF	Ctf1	CPSF160	Binds Pol II Ser5-P and Ser2-P CTD, binds poly(A) site RNA	Promotes Pol II pausing and RNA cleavage for Rat1 entry	N.D.
CPF	Ysh1	CPSF73	Endoribonuclease, cleaves poly(A) site RNA	Provides entry point for Rat1	Provides entry point for exoribonuclease [†]
CPF	Yth1	CPSF30	Binds poly(A) site RNA and Pol II	Promotes Pol II pausing	N.D.
CPF(APT [§])	Glc7	PP1	Ser/Thr phosphatase, dephosphorylates Sen1	N.D.	Promotes Sen1 recruitment and/or helicase activity
CPF (APT)	Pta1	Symplekin	Scaffolding protein, bridges CFIA and CPF	N.D.	Maintains integrity of APT complex
CPF (APT)	Ssu72	SSU72	Pol II Ser5-P CTD phosphatase	Promotes recruitment of Pcf11 to Pol II	Promotes recruitment of Pcf11 to Pol II
Rat1–Rai1–Rtt103	Rat1	XRN2	5'–3' exoribonuclease, degrades Ysh1 (or CPSF73)-generated downstream cleavage product	Promotes Pcf11 and Rna15 recruitment, collides with Pol II near RNA exit channel	No effect observed
Rat1–Rai1–Rtt103	Rai1	DOM3Z	De-capping endoribonuclease, pyrophosphohydrolase	Promotes Rat1 stability and activity	N.D.
Rat1–Rai1–Rtt103	Rtt103	–	Binds Pol II Ser2-P CTD, bridges Rat1 to Pol II CTD	Recruits Rat1 and Pcf11 to Pol II	N.D.
–	–	p54 (also known as NRB and PSF)	RNA-binding proteins, bind Pol II CTD	Promotes XRN2 recruitment to Pol II	N.D.
Sen1–Nrd1–Nab3	Nrd1	SCAF8 and SCAF4	Binds Pol II Ser5-P CTD, RNA-binding protein	No effect observed	Disrupts Pol II hybrid by bridging CTD and RNA, recruits Sen1 to Pol II
Sen1–Nrd1–Nab3	Nab3	–	RNA-binding protein, bridges Nrd1 and Sen1	N.D.	Recruits Sen1 to Pol II
Sen1–Nrd1–Nab3	Sen1	Senataxin	Binds Pol II CTD, 5'–3' RNA-DNA helicase	Promotes Rat1 activity by exposing RNA	Unwinds RNA-DNA hybrid in Pol II
Pol II	Rpb1	RPB1	CTD serves as docking site for transcription and RNA processing factors	Recruits Pcf11 and Rat1 to Pol II	Recruits Nrd1, Pcf11 and Sen1 to Pol II
Pol II	Rpb3	RPB3	Forms heterodimer with Rpb11	N.D.	Transduces termination signal to Pol II
Pol II	Rpb11	RPB11	Forms heterodimer with Rpb3	N.D.	Transduces termination signal to Pol II

Yeast complex	Yeast protein	Human homologue?	Protein function	Putative role in termination	Sen1-dependent	Refs
Paf1C	Paf1	PAF1	Associates with Pol II, scaffolding protein	N.D.	Promotes recruitment of Pef11 and Nrd1 to Pol II	103,138,139
–	Ess1	PIN1	Prolyl-isomerase; binds Ser5-P and Pro6 Pol II CTD	Promotes recruitment of Ssu72 to Pol II [¶]	Promotes recruitment of Ssu72 to Pol II	99,100
–	Ctk1	CDK9	Pol II Ser2 CTD kinase	Promotes recruitment of CFI/A and CPF [§]	Promotes recruitment of Pef11	24,50,89
–	Chd1	CHD1	Chromatin-remodelling factor	Enhances Pol II pausing	N.D.	104

APT, associated with Paf1; CFI/A, cleavage factor IA; Chd1, chromodomain helicase DNA-binding 1; CPF, cleavage and polyadenylation specificity factor; CTD, carboxy-terminal domain; Ctk1, CTD kinase subunit 1; DOM3Z, DOM-3 homologue Z; N.D., not determined; Nab3, nuclear polyadenylated RNA-binding 3; Paf1C, Paf1 complex; Pef11, protein 1 of CFI; PIN1, peptidyl-prolyl *cis-trans* isomerase NIMA-interacting 1; Pol II, RNA polymerase II; PPI, protein phosphatase 1; Rail, Rat1-interacting 1; Rat1, RNA-trafficking protein 1; Rtt103, regulator of Ty1 transposition 103; SCAF, SR-related and CTD-associated factor; Ssu72, suppressor of Sua7 2; XRN2, 5'–3' exoribonuclease 2;

* This is an abbreviated listing owing to space constraints. A more complete table is included in Supplementary information 1 (table).

[†]Termination defects are allele-specific.

[§]APT is a subcomplex of yeast CPF.

[¶]Role in termination seems to be limited to specific mRNAs (for example, short genes and targets of Sen1-dependent attenuation).

[¶]Role in termination seems to be limited to mRNAs with weak poly(A) sites.